Latest Insider Transactions at Spero Therapeutics, Inc. (SPRO)
This section provides a real-time view of insider transactions for Spero Therapeutics, Inc. (SPRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Spero Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Spero Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 26
2021
|
Cristina Larkin Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,067
+48.49%
|
-
|
|
Aug 26
2021
|
Ankit Mahadevia |
BUY
Grant, award, or other acquisition
|
Direct |
78,219
+35.19%
|
-
|
|
Aug 26
2021
|
David A. Melnick Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,067
+50.0%
|
-
|
|
Aug 26
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,982
+0.54%
|
$367,712
$16.55 P/Share
|
|
Aug 24
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,170
+0.94%
|
$642,720
$16.28 P/Share
|
|
Aug 23
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
137,835
+3.19%
|
$2,205,360
$16.33 P/Share
|
|
Aug 20
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
221,190
+5.18%
|
$3,096,660
$14.86 P/Share
|
|
Feb 08
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,000
-0.08%
|
$63,000
$21.74 P/Share
|
|
Feb 04
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,144
-0.88%
|
$614,592
$18.99 P/Share
|
|
Feb 03
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,354
-0.75%
|
$528,372
$18.98 P/Share
|
|
Feb 02
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,841
-0.58%
|
$411,138
$18.99 P/Share
|
|
Feb 01
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,661
-0.35%
|
$259,559
$19.24 P/Share
|
|
Dec 17
2020
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
250,000
-5.98%
|
$4,500,000
$18.81 P/Share
|
|
Dec 16
2020
|
Cristina Larkin Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,000
-88.89%
|
$228,000
$19.0 P/Share
|
|
Dec 16
2020
|
Cristina Larkin Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+47.06%
|
$60,000
$5.9 P/Share
|
|
Dec 16
2020
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
14,933
-0.36%
|
$268,794
$18.62 P/Share
|
|
Nov 09
2020
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
125,900
-2.91%
|
$1,636,700
$13.77 P/Share
|
|
Nov 06
2020
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,000
-0.12%
|
$65,000
$13.77 P/Share
|
|
Nov 05
2020
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
96,600
-2.18%
|
$1,255,800
$13.98 P/Share
|
|
Nov 04
2020
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
72,500
-1.61%
|
$1,015,000
$14.26 P/Share
|
|
Nov 04
2020
|
Ankit Mahadevia |
SELL
Open market or private sale
|
Direct |
7,370
-10.07%
|
$103,180
$14.43 P/Share
|
|
Nov 04
2020
|
Ankit Mahadevia |
BUY
Exercise of conversion of derivative security
|
Direct |
7,370
+9.15%
|
$36,850
$5.9 P/Share
|
|
Nov 03
2020
|
Ankit Mahadevia |
SELL
Open market or private sale
|
Direct |
2,137
-3.14%
|
$29,918
$14.27 P/Share
|
|
Nov 03
2020
|
Ankit Mahadevia |
BUY
Exercise of conversion of derivative security
|
Direct |
2,137
+3.05%
|
$10,685
$5.9 P/Share
|
|
Oct 23
2020
|
Ankit Mahadevia |
SELL
Open market or private sale
|
Direct |
20
-0.03%
|
$280
$14.25 P/Share
|
|
Oct 23
2020
|
Ankit Mahadevia |
BUY
Exercise of conversion of derivative security
|
Direct |
20
+0.03%
|
$100
$5.9 P/Share
|
|
Oct 14
2020
|
Ankit Mahadevia |
SELL
Open market or private sale
|
Direct |
105
-0.16%
|
$1,470
$14.25 P/Share
|
|
Oct 14
2020
|
Ankit Mahadevia |
BUY
Exercise of conversion of derivative security
|
Direct |
105
+0.16%
|
$525
$5.9 P/Share
|
|
Oct 13
2020
|
Ankit Mahadevia |
SELL
Open market or private sale
|
Direct |
14,367
-17.92%
|
$201,138
$14.28 P/Share
|
|
Oct 13
2020
|
Ankit Mahadevia |
BUY
Exercise of conversion of derivative security
|
Direct |
14,367
+15.2%
|
$71,835
$5.9 P/Share
|
|
Jul 17
2018
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
80,000
+3.97%
|
$960,000
$12.5 P/Share
|
|
Nov 06
2017
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
428,571
+18.78%
|
$5,999,994
$14.0 P/Share
|
|
Nov 06
2017
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,425,435
+35.48%
|
-
|